Related references
Note: Only part of the references are listed.Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding
Kyung Chan Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
The molecular function of kallikrein-related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer
Thomas Kryza et al.
MOLECULAR ONCOLOGY (2020)
Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance
Syer C. Lim et al.
FASEB JOURNAL (2020)
Proteases and glycosidases on the surface of exosomes: Newly discovered mechanisms for extracellular remodeling
Ralph D. Sanderson et al.
MATRIX BIOLOGY (2019)
A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1).
Manish A. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The extracellular matrix in tumor progression and metastasis
Johannes A. Eble et al.
CLINICAL & EXPERIMENTAL METASTASIS (2019)
A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential
Emily Gobin et al.
BMC CANCER (2019)
Matrix Metalloproteases as Influencers of the Cells' Social Media
Daniel Young et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma
Gregg B. Fields
CELLS (2019)
The metastasis suppressor, NDRG1, attenuates oncogenic TGF-β and NF-κB signaling to enhance membrane E-cadherin expression in pancreatic cancer cells
Sharleen V. Menezes et al.
CARCINOGENESIS (2019)
Oxaprozin: A new hope in the modulation of matrix metalloproteinase 9 activity
Andrea Ianni et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2019)
Role of Matrix Metalloproteinases in Angiogenesis and Cancer
Saray Quintero-Fabian et al.
FRONTIERS IN ONCOLOGY (2019)
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
Manish A. Shah et al.
CLINICAL CANCER RESEARCH (2018)
Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes
Arthur Winer et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Kallikrein-related peptidase 7 is a potential target for the treatment of pancreatic cancer
Jian Ping Du et al.
Oncotarget (2018)
Extracellular Vesicles and Matrix Remodeling Enzymes: The Emerging Roles in Extracellular Matrix Remodeling, Progression of Diseases and Tissue Repair
Muhammad Nawaz et al.
CELLS (2018)
Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer
Miles A. Miller et al.
CLINICAL CANCER RESEARCH (2017)
Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation
Marcia L. Moss et al.
MEDIATORS OF INFLAMMATION (2017)
Expression of matrix metalloproteinases in Naegleria fowleri and their role in invasion of the central nervous system
Charlton Lam et al.
MICROBIOLOGY-SGM (2017)
The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion
Anup Sharma et al.
MOLECULAR ONCOLOGY (2017)
Structure-Based Discovery of Thiosemicarbazone Metalloproteinase Inhibitors for Hemorrhage Treatment in Snakebites
Francis B. Ferreira et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer.
R. C. Newton et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Metalloproteinases in extracellular vesicles
Masayuki Shimoda et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2017)
New intracellular activities of matrix metalloproteinases shine in the moonlight
Parker G. Jobin et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2017)
The ADAMs family of proteases as targets for the treatment of cancer
Maeve Mullooly et al.
CANCER BIOLOGY & THERAPY (2016)
Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE
Jacob J. Orme et al.
CLINICAL IMMUNOLOGY (2016)
Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs
Agata Jablonska-Trypuc et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2016)
The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms
Zhu-Ling Guo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Zinc(II)-Thiosemicarbazone Complexes Are Localized to the Lysosomal Compartment Where They Transmetallate with Copper Ions to Induce Cytotoxicity
Alexandra E. Stacy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Targeting the Metastasis Suppressor, N-Myc Downstream Regulated Gene-1, with Novel Di-2-Pyridylketone Thiosemicarbazones: Suppression of Tumor Cell Migration and Cell-Collagen Adhesion by Inhibiting Focal Adhesion Kinase/Paxillin Signaling
Xiongzhi Wangpu et al.
MOLECULAR PHARMACOLOGY (2016)
Involvement of Kallikrein-Related Peptidases in Normal and Pathologic Processes
Ana Carolina B. Stefanini et al.
DISEASE MARKERS (2015)
The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the Triad of Death in cancer by Di-2-pyridylketone thiosemicarbazones
Patric J. Jansson et al.
PHARMACOLOGICAL RESEARCH (2015)
Evidence for the Involvement of MMP14 in MMP2 Processing and Recruitment in Exosomes of Corneal Fibroblasts
Kyu-Yeon Han et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2015)
Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy
Bernard A. Fang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2014)
Metastasis of ovarian cancer is mediated by kallikrein related peptidases
Ying Dong et al.
CLINICAL & EXPERIMENTAL METASTASIS (2014)
The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of β-catenin through mechanisms involving FRAT1 and PAK4
Runsen Jin et al.
JOURNAL OF CELL SCIENCE (2014)
The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-Myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway
Jiabei Wang et al.
ONCOTARGET (2014)
The Iron-Regulated Metastasis Suppressor NDRG1 Targets NEDD4L, PTEN, and SMAD4 and Inhibits the PI3K and Ras Signaling Pathways
Zaklina Kovacevic et al.
ANTIOXIDANTS & REDOX SIGNALING (2013)
Novel Chelators for Cancer Treatment: Where Are We Now?
Angelica M. Merlot et al.
ANTIOXIDANTS & REDOX SIGNALING (2013)
Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells
K. M. Dixon et al.
BRITISH JOURNAL OF CANCER (2013)
Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors
Jing Sun et al.
CARCINOGENESIS (2013)
Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer
Mark Sanford
DRUGS (2013)
N-myc Downstream Regulated 1 (NDRG1) Is Regulated by Eukaryotic Initiation Factor 3a (eIF3a) during Cellular Stress Caused by Iron Depletion
Darius J. R. Lane et al.
PLOS ONE (2013)
Extracellular Vesicles Secreted from Cancer Cell Lines Stimulate Secretion of MMP-9, IL-6, TGF-β1 and EMMPRIN
Jasmina S. Redzic et al.
PLOS ONE (2013)
Targeting the Metastasis Suppressor, NDRG1, Using Novel Iron Chelators: Regulation of Stress Fiber-Mediated Tumor Cell Migration via Modulation of the ROCK1/pMLC2 Signaling Pathway
Jing Sun et al.
MOLECULAR PHARMACOLOGY (2013)
The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against Human Lung Tumor Xenografts and Molecular Mechanism of Action
Goldie Y. L. Lui et al.
MOLECULAR PHARMACOLOGY (2013)
Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy
Y. Yu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Expression of Kallikrein-Related Peptidase 7 Predicts Poor Prognosis in Patients with Unresectable Pancreatic Ductal Adenocarcinoma
Vladimir Iakovlev et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2012)
Ectodomain shedding and ADAMs in development
Silvio Weber et al.
DEVELOPMENT (2012)
N-myc downstream regulated gene 1 modulates Wnt-ß-catenin signalling and pleiotropically suppresses metastasis
Wen Liu et al.
EMBO MOLECULAR MEDICINE (2012)
The Iron Chelators Dp44mT and DFO Inhibit TGF-β-induced Epithelial-Mesenchymal Transition via Up-Regulation of N-Myc Downstream-regulated Gene 1 (NDRG1)
Zhiqiang Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Novel Second-Generation Di-2-Pyridylketone Thiosemicarbazones Show Synergism with Standard Chemotherapeutics and Demonstrate Potent Activity against Lung Cancer Xenografts after Oral and Intravenous Administration in Vivo
David B. Lovejoy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
PSA regulates androgen receptor expression in prostate cancer cells
Parmita Saxena et al.
PROSTATE (2012)
Methemoglobin Formation by Triapine, Di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and Other Anticancer Thiosemicarbazones: Identification of Novel Thiosemicarbazones and Therapeutics That Prevent This Effect
Patricia Quach et al.
MOLECULAR PHARMACOLOGY (2012)
Suppression of invasion and metastasis of prostate cancer cells by overexpression of NDRG2 gene
Lei Gao et al.
CANCER LETTERS (2011)
Antitumor Activity of Metal-Chelating Compound Dp44mT Is Mediated by Formation of a Redox-Active Copper Complex That Accumulates in Lysosomes
David B. Lovejoy et al.
CANCER RESEARCH (2011)
Biological role of matrix metalloproteinases: a critical balance
S. Loeffek et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A New Strategy for the Treatment of Pancreatic Cancer
Zaklina Kovacevic et al.
MOLECULAR PHARMACOLOGY (2011)
Cross-domain inhibition of TACE ectodomain
Christopher J. Tape et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Downregulation of NDRG1 promotes invasion of human gastric cancer AGS cells through MMP-2
Yan-li Liu et al.
TUMOR BIOLOGY (2011)
Extracellular Matrix Degradation and Remodeling in Development and Disease
Pengfei Lu et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2011)
To bind zinc or not to bind zinc: An examination of innovative approaches to improved metalloproteinase inhibition
Jennifer A. Jacobsen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2010)
Matrix Metalloproteinases Contribute Distinct Roles in Neuroendocrine Prostate Carcinogenesis, Metastasis, and Angiogenesis Progression
Laurie E. Littlepage et al.
CANCER RESEARCH (2010)
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kai Kessenbrock et al.
CELL (2010)
The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: An EPR study
Patric J. Jansson et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2010)
Novel Thiosemicarbazones of the ApT and DpT Series and Their Copper Complexes: Identification of Pronounced Redox Activity and Characterization of Their Antitumor Activity
Patric J. Jansson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
The regulatory crosstalk between kinases and proteases in cancer
Carlos Lopez-Otin et al.
NATURE REVIEWS CANCER (2010)
Bone morphogenetic protein-4 induced by NDRG2 expression inhibits MMP-9 activity in breast cancer cells
Soo-Kyung Shon et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Active MMP-2 effectively identifies the presence of colorectal cancer
Mary Jo Murnane et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors
Yu Yu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Extracellular and cell surface proteases in wound healing: new players are still emerging
Catherine Moali et al.
EUROPEAN JOURNAL OF DERMATOLOGY (2009)
Specific targeting of metzincin family members with small-molecule inhibitors: Progress toward a multifarious challenge
Dimitris Georgiadis et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2008)
Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors
Rajesh Subramaniam et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis
Dong Chul Lee et al.
CANCER RESEARCH (2008)
Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor
Lois Witters et al.
CANCER RESEARCH (2008)
A macrophage cell model for selective metalloproteinase inhibitor design
Faith E. Jacobsen et al.
CHEMBIOCHEM (2008)
Intracellular-co-localization of trypsin-2 and matrix metalloprotease-9: Possible proteolytic cascade of trypsin-2, MMP-9 and enterokinase in carcinoma
Suvi-Tuuli Vilen et al.
EXPERIMENTAL CELL RESEARCH (2008)
Proteases: Multifunctional Enzymes in Life and Disease
Carlos Lopez-Otin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Specific binding of divalent metal ions to tetracycline and to the Tet repressor/tetracycline complex
Gottfried J. Palm et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2008)
Secretion of Active Membrane Type 1 Matrix Metalloproteinase (MMP-14) Into Extracellular Space in Microvesicular Exosomes
Juha Hakulinen et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2008)
CD147, MMP-1, MMP-2 and MMP-9 Protein Expression as Significant Prognostic Factors in Human Prostate Cancer
Wei-de Zhong et al.
ONCOLOGY (2008)
MMPs as therapeutic targets - Still a viable option?
Barbara Fingleton
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2008)
Iron chelation by clinically relevant anthracyclines: Alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking
X. Xu et al.
MOLECULAR PHARMACOLOGY (2008)
The ADAMs: signalling scissors in the tumour microenvironment
Gillian Murphy
NATURE REVIEWS CANCER (2008)
A novel series of highly selective inhibitors of MMP-3
Gavin A. Whitlock et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Tumour micro environment -: Opinion -: Emerging roles of proteases in tumour suppression
Carlos LOpez-Otin et al.
NATURE REVIEWS CANCER (2007)
Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling
Charlotte Kopitz et al.
CANCER RESEARCH (2007)
Chelators at the cancer coalface: Desferrioxamine to triapine and beyond
Yu Yu et al.
CLINICAL CANCER RESEARCH (2006)
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics
Megan Whitnall et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Design and synthesis of novel metalloproteinase inhibitors
Shingo Nakatani et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
Trypsins and their role in carcinoma growth
P Nyberg et al.
EXPERIMENTAL CELL RESEARCH (2006)
Towards third generation matrix metalloproteinase inhibitors for cancer therapy
CM Overall et al.
BRITISH JOURNAL OF CANCER (2006)
Structure and function of matrix metalloproteinases and TIMPs
H Nagase et al.
CARDIOVASCULAR RESEARCH (2006)
Zinc(II) complexes derived from pyridine-2-carbaldehyde thiosemicarbazone and (1E)-1-pyridin-2-ylethan-1-one thiosemicarbazone. Synthesis, crystal structures and antiproliferative activity of zinc(II) complexes
Dimitra Kovala-Demertzi et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2006)
Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells
TL Veveris-Lowe et al.
ENDOCRINE-RELATED CANCER (2005)
High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma
J Nikkola et al.
CLINICAL CANCER RESEARCH (2005)
Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer
A Bjartell et al.
PROSTATE (2005)
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of NIMP-2 and MT1-MMP
A Rossello et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Crystal structures of MMPs in complex with physiological and pharmacological inhibitors
K Maskos
BIOCHIMIE (2005)
Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer
A Janowska-Wieczorek et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells
A Boire et al.
CELL (2005)
Adams: Key components in EGFR signalling and development
CP Blobel
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies
BG Rao
CURRENT PHARMACEUTICAL DESIGN (2005)
Timeline - The discovery of receptor tyrosine kinases: targets for cancer therapy
A Gschwind et al.
NATURE REVIEWS CANCER (2004)
Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands
U Sahin et al.
JOURNAL OF CELL BIOLOGY (2004)
Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment
J Yuan et al.
BLOOD (2004)
Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group Trial E2196
JA Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Sultam hydroxamates as novel matrix metalloproteinase inhibitors
RJ Cherney et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation
NTV Le et al.
BLOOD (2004)
Matrix metalloproteinases and their tissue inhibitors in the developing neonatal mouse uterus
JB Hu et al.
BIOLOGY OF REPRODUCTION (2004)
Extracellular proteases as targets for treatment of cancer metastases
M Lee et al.
CHEMICAL SOCIETY REVIEWS (2004)
Molecular mechanisms of tumor invasion and metastasis: An integrated view
RA Cairns et al.
CURRENT MOLECULAR MEDICINE (2003)
Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface
A Remacle et al.
JOURNAL OF CELL SCIENCE (2003)
Physiological levels of tumstatin, a fragment of collagen IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αVβ3 integrin
Y Hamano et al.
CANCER CELL (2003)
Identification of SAP97 as an intracellular binding partner of TACE
F Peiretti et al.
JOURNAL OF CELL SCIENCE (2003)
Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1,-8,-13) and stromelysin-1 (MMP-3) and degrades type I collagen
M Moilanen et al.
BIOCHEMISTRY (2003)
Human kallikrein 6 (hK6): A new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma
EP Diamandis et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
TACE is required for the activation of the EGFR by TGF-α in tumors
M Borrell-Pagès et al.
EMBO JOURNAL (2003)
MMP-9 activation by tumor trypsin-2 enhances in vivo invasion of human tongue carcinoma cells
P Nyberg et al.
JOURNAL OF DENTAL RESEARCH (2002)
Evidence for regulation of the tumor necrosis factor α-convertase (TACE) by protein-tyrosine phosphatase PTPH1
YF Zheng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The role of iron in cell cycle progression and the proliferation of neoplastic cells
NTV Le et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2002)
Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide
GA Bannikov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations
LM Coussens et al.
SCIENCE (2002)
Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma
SP Mönig et al.
HISTOPATHOLOGY (2001)
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
G Bergers et al.
NATURE CELL BIOLOGY (2000)
Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model
JM Fang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Trypsin stimulates integrin α5β1-dependent adhesion to fibronectin and proliferation of human gastric carcinoma cells through activation of proteinase-activated receptor-2
S Miyata et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Matrix metalloproteinases in tumor invasion
N Johansson et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2000)
Share Paper
